Michael Wang

last updated 4/4/2018

Michael L. Wang

Professor at The University of Texas MD Anderson Cancer Center

Location:
1515 Holcombe Blvd., Houston, Texas, United States
HQ Phone:
(713) 792-2121

General Information

Education

MD

Recent News  

US FDA approves AstraZeneca's Calquence (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma

Michael L. Wang, MD, Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, and Principal Investigator of the ACE-LY-004 MCL clinical trial, said: "The acalabrutinibapproval represents an important development for patients currently battling mantle cell lymphoma, an aggressive type of blood cancer that is typically diagnosed at an advanced stage and associated witha high relapse rate.

Read More
22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma | Online CME Activities

Michael Wang, MD
Professor, Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center

Read More
US FDA APPROVES ASTRAZENECA'S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA - Detail - Life Sciences Community Oss

Michael L. Wang, MD, Professor, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, and Principal Investigator of the ACE-LY-004 MCL clinical trial, said: "The acalabrutinib approval represents an important development for patients currently battling mantle cell lymphoma, an aggressive type of blood cancer that is typically diagnosed at an advanced stage and associated with a high relapse rate.

Read More

Browse ZoomInfo’s Directories